suMMARY The aim of the present study was to determine the strength of the relation between serum creatine kinase isoenzyme MB estimated infarct size, other prognostic variables, and mortality after acute myocardial infarction. Serum creatine kinase MB estimated infarct size and 11 other prognostic variables were obtained in 317 patients. By Cox regression analysis the prognostic variables significantly related to mortality were identified: congestive heart failure, estimated infarct size, New York Heart Association class, number of previous infarcts, and age. Congestive heart failure and estimated infarct size were most strongly related to mortality. The relation between the prognostic variables and mortality was non-linear, and the variables influenced each others' relation to mortality. A prognostic index based on all five prognostic variables provided the best means of estimating the probability of survival after acute myocardial infarct. Neither serum creatine kinase MB estimated infarct size nor any of the other prognostic variables had a significant independent influence on mortality, and the probability of survival was high in the absence of any of the prognostic variables in combination. 
suMMARY The aim of the present study was to determine the strength of the relation between serum creatine kinase isoenzyme MB estimated infarct size, other prognostic variables, and mortality after acute myocardial infarction. Serum creatine kinase MB estimated infarct size and 11 other prognostic variables were obtained in 317 patients. By Cox regression analysis the prognostic variables significantly related to mortality were identified: congestive heart failure, estimated infarct size, New York Heart Association class, number of previous infarcts, and age. Congestive heart failure and estimated infarct size were most strongly related to mortality. The relation between the prognostic variables and mortality was non-linear, and the variables influenced each others' relation to mortality. A prognostic index based on all five prognostic variables provided the best means of estimating the probability of survival after acute myocardial infarct. Neither serum creatine kinase MB estimated infarct size nor any of the other prognostic variables had a significant independent influence on mortality, and the probability of survival was high in the absence of any of the prognostic variables in combination.
During recent years methods for the in vivo estimation of infarct size have been developed since the extent of an acute myocardial infarct influences prognosis.' 2 Methods of estimating infarct size based on serial serum creatine kinase and creatine kinase isoenzyme MB activities correlate closely with the extent of necrosis measured at necropsy.3 4 Creatine kinase isoenzyme MB estimated infarct size has also correlated well with Grande, Neilsen, Wagner, Christiansen considered: ventricular extrasystoles, tachycardia and fibrillation, sinus arrest, supraventricular extrasystoles and tachycardia, second and third degree atrioventricular block, and asystole. Cardiac arrest was defined as ventricular fibrillation or asystole. The New York Heart Association functional class of symptoms of heart failure was estimated on day 7.
CALCULATION OF INFARCT SIZE
The estimation of infarct size by serum creatine kinase isoenzyme activity is based on the equation:
is the specific creatine kinase isoenzyme MB activity (U/1) in serum at time t (hours). The function f(t) is the appearance function-that is, the hypothetical value for dE/dt without elimination. The factor kd is the elimination constant (assuming first order kinetics). T is the time until creatine kinase isoenzyme MB activity can no longer be detected. We used the compartment as a model, which is described in detail elsewhere.4
FOLLOW UP
The patients were followed after discharge at intervals depending on late complications. Nevertheless, all survivors were given a full clinical examination one year after discharge. The time of death was ascertained as far as possible, either on readmission to hospital or by communication with the official registrar of persons and, when necessary, with relatives. The follow up was 100%.
STATISTICAL MODEL
The survival data were analysed by a regression model originally proposed by Cox.'5 The simplest formulation of Cox's model is as a model for the death rate X(t), which uniquely determines the distribution of survival time. X(t) can be thought of as the probability of dying on the t-th day, assuming that the patient survived the first t-l days. X(t) is assumed to depend on certain prognostic factors (covariates) and to Andersen'8 whether the effects of various covariates can be described adequately by proportionality factors as mentioned above, and whether they enter the linear way, which the model assumes.
Not all the prognostic factors (Table 1) were available on the day of admission; for example, the estimate of infarct size was first available on the second or third day. The incidence of rhythm disturbances and cardiogenic shock was highest during the first days of admission. We chose to use the information available during the seven days after admission for practical reasons. By day 7 most of the serious complications had appeared, the clinical course has been determined, and the long term treatment plan had to be developed.
The evaluation of the variables was begun by using the 12 covariates shown in Table 1 . The model was then reduced to a minimal set of covariates with a significant influence on the prognosis-that is the covariates from the set originally considered which did not contribute significantly to the prognosis were eliminated. Furthermore, we checked by a graphical technique'8 whether the effect of the covariates could be described by proportionality factors and whether they entered in a linear fashion. In cases where this was not so, the covariates were transformed accordingly. A prognostic index was defined as: prognostic 
Results
Forty of the 274 (15%) patients who were alive on the seventh day died within the first year. Table 2 shows the prognostic variables which were significantly related to the one year survival: number of previous infarcts, age, estimated infarct size, heart failure, and NYHA class. Inclusion of other variables did not contribute significantly to the estimated prognosis. Graphical analysis showed that age-and estimated infarct size had to be transformed to fit the model, and that NYHA class should enter as a bivariate (NYHA 1 or > 1). Table 3 shows the estimates of the regression coefficients f, estimates of the standard deviations for these, the statistic (3j,/SD (pi) and the corresponding p values. 31i/SD (pi) is an approximate standard normal deviate when 8i =0, so that it yields a test for the hypothesis that one of the covariates in the model is without effect, assuming that the other covariates are still taken into account. Heart failure and creatine kinase isoenzyme estimated infarct size were the prognostic variables most strongly related to mortality.
To illustrate the prognostic value of the estimated infarct size, the estimated survival function for two values of estimated infarct size are shown in Fig. 1 . The estimated infarct sizes were 200 U/I (10 g) and 2000 U/1(-120 g), and the other four significantly important prognostic variables were equal. The one year probability of survival was 0*87 and 0*69 respectively. Figures 2 and 3 show the probability of survival as a function of time; (a and (b) compare the effects of the qualitative variable on the probability of survival. The effects of the quantitative variable (age and estimated infarct size) are compared by considering Fig, 2a  against 2b and Fig. 3a against 3b respectively. For the different ages and estimated infarct sizes illustrated, the presence of heart failure was the most important single prognostic variable followed by NYHA class Fig. 1 Probability of survival at least t days after the seventh day after admission, assuming that the patient was alive on day 7, for two patients aged 55 years old, in NYHA class >1, with no previous infarcts, and no heart failure. The patient indicated by the upper line had an estimated infarct size of200 Ull, the other (lower line) one of2000 Ull. Bars represent I SD. > 1 and the presence of previous infarcts. The clinical importance of large infarct size or older age changes rapidly with the presence of other prognostic variables. Figure 4 shows the relation between creatine kinase isoenzyme MB estimated infarct size and the probability of one year survival. The upper function represents a low risk combination of the other prognostic variables, the lower function a high risk combination. In patients without other poor prognostic variables the overall prognosis is good, and the clinical importance of the estimated infarct size is small. In the presence of other poor prognostic variables the probability of survival deteriorates rapidly as a function of infarct size. The difference in probability of one year survival between patients at low and high risk ranges between 8% and 35% depending on the estimated infarct size. Figure 5 summarises the results of the analyses and shows the relation between the prognostic index (PI) and the probability of one year survival. The presence of few risk factors-that is, PI<10-11-indicates a very high probability of one year survival. A prognostic index above this level indicates a rapidly deteriorating one year prognosis.
Discussion
Recently estimated infarct size has been shown to be a prognostic variable which significantly influences the short as well as long term prognosis after acute myocardial infarction.'0'2 The aims of the present study were to quantify the relation between creatine kinase isoenzyme MB estimated infarct size and mortality and to determine its clinical importance in relation to other prognostic variables.
Two types of studies have been performed to evaluate the relation between serum enzyme estimated infarct size and mortality. Most studies have found an increased mean peak enzyme value or high estimated infarct size in those who died compared with survivors.9 19 20 These studies, however, provide no information on the prediction of the probability of mortality. Two studies have shown that in patients stratified according to creatine kinase or creatine kinase isoenzyme MB estimated infarct size, there is a significant prospective relation between estimated infarct size and mortality.'012 Nevertheless, neither the strength of the relation as a function of infarct size nor the influence on the relation of other prognostic variables have been determined.
The present study confirms that the creatine kinase isoenzyme MB estimated infarct size is a significant prognostic variable for mortality ( Table 3) . As shown previously, the mortality is highest during the first months after infarction (Fig. 1) .10 12 The influence of infarct size on the probability of one year survival is, however, dependent on the other prognostic variables (Fig. 2) . In the absence of the other variables negatively influencing prognosis, the estimated infarct size has little influence on the probability of one year survival (Fig. 3) . In the presence of these other prognostic variables the probability of one year survival is more influenced by infarct size (Fig. 4) .
The 12 covariates estimated in the present study 12 Grande, Neilsen., Wagner., Christiansen have previously been shown to be related to mortality after infarction. CK-MB, creatine kinase isoenzyme.
Grande, Neilsen, Wagner, Christiansen dures, and the correlation between serum creatine kinase estimated infarct size and infarct size measured at necropsy is relatively low (r=0-63, SEE=42%). 4 In the present study, however, infarct size was estimated by a method based on measurements of the heart specific enzyme creatine kinase isoenzyme MB. This method has proved to be reliable for estimating infarct size in man, which is closely related to the extent of necrosis measured at necropsy (r=0.85, SEE=25%). 4 The use of creatine kinase isoenzyme MB estimation provides an inexpensive, readily available noninvasive method for estimating infarct size. This method might be of primary importance for two main clinical reasons. Firstly, it may be useful as an endpoint in clinical trials aimed at limiting the extent of myocardial damage during myocardial infarction. Secondly, the clinician might use the estimated infarct size to determine the prognosis after infarction. The main purpose, however, of assessing the prognosis is to be able to improve treatment of the diseased patient. Thus, although a reliably estimated infarct size seems to be valuable for determining the prognosis, further clinical trials are needed to show if treatment based on the estimated infarct size improves the prognosis after an infarction. creatine kinase estimated infarct size and heart failure were the two variables most significantly associated with mortality after infarction. ' 
